# 2025-08872: FDA Starts Reworking the Fees Behind Generic Drug Approvals

2025-08872, Reauthorization of the Generic Drug User Fee Amendments; Public Meeting; Request for Comments, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-05-19, effective FDA will seek reauthorization to collect Generic Drug User Fees for fiscal years 2028 through 2032; new legislation will be required by the end of September 2027. Public meeting: July 11, 2025; written or electronic comments due by August 11, 2025.; PRIA reads it as touching household money (as of 2026-10-21).

- Canonical: https://policyrisk.com/federal-register/2025-08872
- As of: 2026-10-21
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-08872
- Title: Reauthorization of the Generic Drug User Fee Amendments; Public Meeting; Request for Comments
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 21313
- Published: 2025-05-19
- Effective: FDA will seek reauthorization to collect Generic Drug User Fees for fiscal years 2028 through 2032; new legislation will be required by the end of September 2027. Public meeting: July 11, 2025; written or electronic comments due by August 11, 2025.
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-21

## In one line

FDA Starts Reworking the Fees Behind Generic Drug Approvals

## Summary

The FDA is gearing up to renew the Generic Drug User Fee program for 2028-2032, which helps fund faster approval of generic medicines. They’re hosting a public meeting on July 11, 2025, and want your ideas on how to improve the program before collecting fees again. If you’re involved in making or using generic drugs, this is your chance to shape the future—and don’t forget to send your comments by August 11, 2025!

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is hosting a public meeting on the reauthorization of the Generic Drug User Fee Amendments (GDUFA) for fiscal years (FYs) 2028 to 2032. At the end of September 2027, new legislation will be required for FDA to continue to collect generic drug user fees for future FYs. The Federal Food, Drug, and Cosmetic Act (FD&C Act) requires that before FDA begins negotiations with the regulated industry on GDUFA reauthorization, we publish a notice in the Federal Register requesting public input on the reauthorization; hold a public meeting at which the public may present its views on the reauthorization, including specific suggestions for changes to the goals referred to in the GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023-2027 (i.e., the GDUFA III Commitment Letter) (https://www.fda.gov/industry/ generic-drug-user-fee-amendments/gdufa-iii-reauthorization); provide a period of 30 days after the public meeting to obtain written comments from the public; and publish the comments on FDA's website. FDA invites public comment on the GDUFA program and suggestions regarding the features FDA should propose for the next GDUFA program cycle. These comments will be published and available on FDA's website.

## Effects PRIA read

- Generic drug makers must pay user fees: cost, medium. If you make or submit generic drug applications, the FDA's GDUFA program requires that generic drug manufacturers and related entities pay user fees for certain generic drug applications, drug master files, and facilities. FDA is seeking reauthorization to collect these fees for fiscal years 2028 t…
- User fees fund faster generic drug access: benefit, medium. You may get faster access to generic medicines because FDA says the GDUFA program uses collected user fees to finance program enhancements aimed at reducing the number of assessment cycles for abbreviated new drug applications and to foster development and approval of complex generic products. Thes…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-08872 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/19/2025-08872/reauthorization-of-the-generic-drug-user-fee-amendments-public-meeting-request-for-comments)
- [2025-08872 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-19/pdf/2025-08872.pdf)

## Related
- [Previous: 2025-08871, South Atlantic Fishery Management Council; Public Meeting](https://policyrisk.com/federal-register/2025-08871)
- [Next: 2025-08873, Agency Information Collection Activities; Comment Request; Standard Job Corps C…](https://policyrisk.com/federal-register/2025-08873)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-08872 (as of 2026-10-21).
